|
gptkbp:instanceOf
|
gptkb:drug
gptkb:angiotensin_II_receptor_blocker
|
|
gptkbp:approvalYear
|
1997
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
C09CA04
|
|
gptkbp:availableOn
|
gptkb:tablet
|
|
gptkbp:brand
|
gptkb:Aprovel
Avapro
Irovel
Karvea
|
|
gptkbp:CASNumber
|
138402-11-6
|
|
gptkbp:category
|
gptkb:sartan
gptkb:antihypertensive_agent
|
|
gptkbp:chemicalFormula
|
C25H28N6O
|
|
gptkbp:contraindication
|
pregnancy
bilateral renal artery stenosis
|
|
gptkbp:developedBy
|
gptkb:Sanofi
|
|
gptkbp:drugClass
|
angiotensin receptor blocker
|
|
gptkbp:eliminationHalfLife
|
11-15 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:firstSynthesized
|
1990s
|
|
gptkbp:interactsWith
|
gptkb:NSAIDs
gptkb:aliskiren
lithium
potassium-sparing diuretics
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
gptkb:angiotensin_II_receptor_antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
428.53 g/mol
|
|
gptkbp:notRecommendedFor
|
pregnant women
breastfeeding women
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:prescribes
|
adults
children over 6 years (in some countries)
|
|
gptkbp:proteinBinding
|
90%
|
|
gptkbp:riskFactor
|
gptkb:angioedema
renal impairment
hyperkalemia
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
hypotension
hyperkalemia
|
|
gptkbp:usedFor
|
hypertension
diabetic nephropathy
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Aprovel
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
irbesartan
|